A groundbreaking single-cell study has unveiled crucial immunological disruptions in type 2 diabetes, linking specific chemokines to disease progression. By dissecting immune cell populations and their roles, the atlas illuminates the inflammatory mechanisms underpinning T2D beyond metabolic factors. These insights offer pathways for new immunomodulatory interventions aimed at treating or preventing type 2 diabetes.